David Borges Sells 30,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 30,000 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Omeros Trading Down 6.7%

OMER stock opened at $12.21 on Friday. The firm has a 50 day moving average of $11.05 and a 200-day moving average of $6.90. The firm has a market capitalization of $865.69 million, a P/E ratio of -6.04 and a beta of 2.38. Omeros Corporation has a 12 month low of $2.95 and a 12 month high of $17.65.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.39. Sell-side analysts predict that Omeros Corporation will post -3.09 EPS for the current year.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently bought and sold shares of the company. B. Riley Wealth Advisors Inc. bought a new position in Omeros during the second quarter valued at approximately $32,000. Harbour Investments Inc. boosted its stake in shares of Omeros by 46.1% in the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,251 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,971 shares during the last quarter. Sei Investments Co. purchased a new position in Omeros in the 2nd quarter worth $40,000. Finally, Russell Investments Group Ltd. lifted its stake in Omeros by 113.1% in the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on OMER shares. WBB Securities reissued a “strong-buy” rating and set a $45.00 price objective on shares of Omeros in a research note on Wednesday, October 15th. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. HC Wainwright lifted their target price on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Wall Street Zen lowered shares of Omeros from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Omeros presently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.